Sage — The Metabolic Hypothesis of Arterial and Venous Occlusions

← Sage — Ophthalmology · Sage — Eye · Sage hub

Sage — The Metabolic Hypothesis of Arterial and Venous Occlusions

Occlusion as Catastrophic Mismatch: When the Flux Manager Fails the Conduit

Disclaimer · This essay presents a metabolic and evolutionary hypothesis developed through first-principles reasoning, integration of mechanistic biology, clinical patterns (particularly from ophthalmology), and the unifying EnSurf metabolic framework. It is offered for educational and philosophical purposes only. It is not medical advice, diagnosis, or treatment. Statins, GLP-1 receptor agonists, antiplatelet agents, anticoagulants, and other pharmacologic tools have robust evidence for specific indications in appropriately selected patients; they are not dismissed. Individual responses vary widely. Decisions about starting, continuing, or stopping any prescription medicine, or about significant changes to diet, lifestyle, or supplements, belong solely to a patient and a qualified clinician who know the full clinical context. Readers with existing vascular disease, crowded optic discs, or who take nitrates or other vasoactive drugs should consult their physician before making changes.

The eye is a high-resolution prototype of vascular failure. Its arteries and veins are small, share adventitial sheaths where they cross and inside the optic nerve, and serve tissue that reports injury within minutes as lost vision. Central and branch retinal artery occlusions, and central and branch retinal vein occlusions, therefore function as clinical microscopes. They make visible, at the scale of a single vascular bed, the same upstream processes that later declare themselves as coronary occlusion, cerebral infarction, deep-vein thrombosis, or pulmonary embolism. The traditional separation of “arterial” and “venous” disease is clinically useful and mechanistically incomplete. Both converge on the same metabolic root: progressive loss of coupled endothelial nitric oxide and mitochondrial competence in the vessel wall. The catastrophic events—embolus, in-situ thrombosis, compressive venous stasis, hemorrhage, infarction—are downstream expressions of that root, not independent diseases.

This essay places arterial and venous occlusion inside the mitochondrial-metabolic hypotheses of atherosclerosis and of nitric oxide. This essay treats the retina as the proving ground, then scales the same logic to the organism. It also examines how dashboard interventions (statins, GLP-1 receptor agonists) can modulate downstream cascades while leaving the engine unrepaired, and how ferritin metabolism—iron sequestration as a sentinel of redox and bioenergetic coherence—may contribute to the prothrombotic milieu of venous occlusion.

Where Separate Disease Models Fall Short

Standard teaching distinguishes arterial from venous occlusion by hemodynamics and thrombus composition. Arterial events occur under high shear. They are driven by atherosclerotic plaque rupture or embolism and produce platelet-rich (“white”) thrombi that starve downstream tissue of oxygen. Venous events occur under low shear. They follow Virchow’s triad—stasis, endothelial injury or activation, and hypercoagulability—and produce fibrin- and erythrocyte-rich (“red”) thrombi that raise hydrostatic pressure, leak, and secondarily ischemia. In the eye the distinction is sharp: retinal artery occlusion behaves as an ocular stroke with high subsequent systemic vascular risk; retinal vein occlusion is more often managed as a local congestive and edematous problem, though it too tracks cardiovascular risk factors.

These descriptions are accurate as far as they go. They do not explain why the same middle-aged patient develops both, why endothelial dysfunction appears years before either event, why lean individuals with efficient mitochondria can carry high apoB without plaque while insulin-resistant individuals progress at modest particle numbers, or why interventions that restore laminar shear and mitochondrial oxidative capacity reduce risk of both arterial and venous events more reliably than interventions aimed only at the final thrombus. Treating the two as separate disease families requires multiple independent inputs (lipids, hypertension, hypercoagulability, local anatomy) converging by coincidence. A single upstream failure of energy-flux management accounts for more of the data with fewer entities.

The Metabolic Hypothesis

Arterial and venous occlusions are catastrophic mismatches between mitochondrial demand and the ability of the conduit to deliver oxygen and substrate while remaining patent. The primary defect is the progressive uncoupling of endothelial nitric oxide synthase and the mitochondrial inefficiency that both produces and is worsened by that uncoupling. Atherosclerosis is the arterial expression of conduit failure. Venous occlusion is the low-shear expression of the same endothelial and rheologic vulnerability, amplified by local anatomy and stasis.

Nitric oxide remains the short-range flux manager. It opens feed arteries in response to shear, modestly rations oxygen consumption at cytochrome c oxidase so proximal mitochondria do not monopolize the terminal acceptor, and restrains leukocyte adhesion, platelet activation, and smooth-muscle proliferation so the lumen stays competent. When eNOS is coupled and mitochondria oxidize cleanly, high energy flux is possible without proportional damage. When superoxide uncouples the enzyme, the manager becomes a source of peroxynitrite. Delivery fails, matching fails, and the wall begins the program that ends in plaque or in a vein that can no longer tolerate ordinary compression and stasis.

In arterial territories the failure is expressed as atherogenesis. Endothelial permeability rises, apoB particles are retained, oxidized, and taken up by macrophages whose own mitochondria are impaired. Foam cells, fibrous caps, and necrotic cores follow. The final occlusion may be plaque rupture with superimposed thrombosis or embolism from a distant unstable site; the initiating lesion is the loss of tonic NO and the mitochondrial distress that permitted retention and inflammation. The retina simply makes the endpoint dramatic: an embolus or local thrombus in the central retinal artery takes vision within seconds, and the retina turns pale with a cherry-red spot over the following hours, because the inner retina has almost no collateral reserve.

In venous territories the same endothelial impairment meets different local physics. At arteriovenous crossings the artery and vein share an adventitial sheath. Arteriosclerotic stiffening of the artery narrows the vein, produces turbulent flow, and injures endothelium. In the lamina cribrosa the central retinal artery and vein are likewise enclosed together. Elevated intraocular pressure further impedes venous outflow. When the endothelium is already adhesive and prothrombotic from NO loss, ordinary compression and modest hyperviscosity are sufficient to initiate thrombus. The resulting congestion raises hydrostatic pressure, breaks the blood-retinal barrier, and produces the hemorrhages, edema, and secondary ischemia of retinal vein occlusion. Systemically the same logic operates in valve pockets of the deep veins: hypoxia of the avascular cusp endothelium, leukocyte recruitment, and local tissue-factor expression on a background of systemic hypercoagulability that itself tracks insulin resistance and mitochondrial dysfunction.

The two pathways therefore share the upstream metabolic lesion and diverge only in the geometry and shear environment that convert that lesion into occlusion. Atherosclerosis is not required for every venous event, yet the endothelial vulnerability that permits venous thrombosis is the same vulnerability that permits arterial plaque. Hypercoagulable states, dehydration, and hormonal modulation of clotting factors act as precipitants on a prepared surface; they are not the root.

Ferritin, Iron Handling, and the Prothrombotic Milieu

Ferritin is conventionally read as a storage ledger of iron atoms. A metabolic reading treats it as an active sentinel of bioenergetic integrity and redox coherence. Iron is indispensable for iron-sulfur clusters and heme in the electron-transport chain and dangerous as a Fenton catalyst. When the cell registers rising reactive oxygen species (via Nrf2) or inflammatory cytokines (via STAT3, NF-κB, and hepcidin), it upregulates ferritin to sequester ferrous iron as ferric iron inside the protein cage. The result is protective containment. In chronic low-grade redox and inflammatory states—the same states that uncouple eNOS and impair mitochondrial quality control—this sequestration becomes persistent. Transferrin saturation may fall while ferritin rises. Functional iron availability for erythropoiesis and for mitochondrial biogenesis is restricted even as stored iron is adequate or elevated. Labile iron that escapes containment continues to generate localized oxidative damage.

This pattern is relevant to venous hypercoagulability. Endothelial cells under chronic redox pressure express more adhesion molecules and tissue factor. Macrophages sequestering iron release mtDAMPs and cytokines that further activate coagulation. Iron deficiency itself (or functional iron deficiency) is associated with reactive thrombocytosis and endothelial dysfunction that favor thrombosis. Metabolic hyperferritinemia, common in insulin resistance and fatty liver, tracks the same bioenergetic milieu that elevates apoB and impairs NO bioavailability. In the eye, where shared sheaths already concentrate mechanical stress onto the venous wall, an endothelium whose iron handling is shifted toward containment rather than clean utilization is more readily driven across the threshold into thrombus by ordinary compression or modest stasis. Ferritin is not the cause of occlusion. It is a readable signal that the organism is prioritizing containment of a redox threat over free distribution of iron in service of oxidative phosphorylation. Resolving the threat—by restoring fuel quality, shear, and circadian amplitude—can lower the drive to sequester and improve the functional iron available for mitochondrial and endothelial repair.

The Eye as Prototype and as Canary

Retinal vessels are an experimental system that evolution and clinical medicine have already built. They are optically accessible, small enough that single emboli or focal thrombi produce measurable field defects, and anatomically arranged so that arterial disease directly injures the companion vein. Branch retinal vein occlusion almost always occurs at an arteriovenous crossing, usually where the artery lies over the vein. Central retinal vein occlusion occurs where the vessels share the fibrous envelope of the lamina cribrosa. These sites concentrate the mechanical consequence of arterial stiffening onto the venous wall. The eye therefore displays, in one vascular bed, the full sequence: mitochondrial and NO failure in the arterial wall → arteriosclerosis and endothelial dysfunction → local venous compression and endothelial injury → thrombosis → congestion, hemorrhage, macular edema, and ischemia.

The clinical epidemiology follows. Both retinal artery and vein occlusions rise with age and with the classic metabolic risk factors. Arterial occlusions carry a clearer short-term stroke and cardiac risk because they more often represent embolization from unstable extracranial or cardiac sources—the same sources that threaten the brain. Venous occlusions track hypertension, glaucoma, and the metabolic syndrome more tightly and carry a lower but still elevated systemic risk. In younger patients without conventional risk factors, thrombophilia (antiphospholipid antibodies, factor V Leiden, hyperhomocysteinemia) becomes visible precisely because the background endothelial resilience is higher; the precipitant must be stronger. The prototype predicts that interventions restoring laminar shear, coupled eNOS, and mitochondrial oxidative capacity will reduce both events, while interventions aimed only at the final clot will treat the catastrophe after the conduit has already failed.

The optic nerve head adds a further watershed. Non-arteritic anterior ischemic optic neuropathy is an ischemic-bioenergetic failure of the anterior optic nerve in a crowded disc. Perfusion reserve collapses, axonal transport fails, the disc swells in a tight scleral canal, and vision is often permanently cut. This anatomy is especially sensitive to sudden changes in perfusion pressure, nocturnal blood pressure, viscosity, and nutrient delivery. It is also a tissue whose axons are lifelong and cannot be freely recycled from stem-cell pools. When dashboard interventions rewrite load and substrate availability faster than mitochondrial capacity can adapt, the optic nerve is a plausible site of declaration.

Dashboard Interventions and the Optic Nerve

Statins inhibit HMG-CoA reductase at the mouth of the mevalonate pathway. Cholesterol is one product; ubiquinone (CoQ10), dolichols, and isoprenoids required for protein prenylation are others. CoQ10 is the mobile electron carrier between complexes I/II and III. Experimental systems show statin effects on membrane potential, respiratory complexes, and mitochondrial ROS. In secondary prevention they reduce plaque events, and some observational studies associate their use with lower rates of retinal vascular occlusion and with reduced subsequent cardiovascular events after either arterial or venous occlusion. These benefits are real and operate largely by lowering circulating apoB substrate, stabilizing plaque, and modulating inflammatory cascades. They do not restore oxidative phosphorylation capacity in the vascular wall or in high-demand axons. They are sophisticated dashboard work. Over-emphasizing them as engine repair confuses a lower particle number and quieter intima with rebuilt mitochondrial reserve.

GLP-1 receptor agonists override appetite circuits, gastric emptying, and glucose-dependent insulin secretion. Weight, glucose, and often MACE improve. They do not repair electron-transport function. In some trials a large share of weight lost is lean mass, though the share varies widely and lean mass is not the same as muscle. Rapid glycemic change can alter microvascular flow and nutrient delivery. In the combination—statin taxing mevalonate products while GLP-1 rewrites phenotype and often spends lean mass—the dashboard turns greener while the gap between ATP supply and demand may widen in watershed tissues. Observational signals of roughly two-fold increased NAION risk with semaglutide are compatible with a low-absolute-incidence tail-risk energy-failure lesion inside a beneficial average MACE curve. Absolute excess is small (on the order of one extra case per ten thousand person-years in some estimates). The mechanism is not “two toxins.” It is reduced ETC reserve plus forced phenotype change plus a green dashboard that hides the gap, concentrated, on this hypothesis, where crowded discs, sleep apnea, and nocturnal hypotension (established NAION risk factors) coincide with rapid early weight and A1c decline, high-intensity statin, and low baseline muscle.

Neither drug is dismissed. Both can buy time by unloading the vessel wall and lowering inflammatory drive. The incomplete act is to stop there and call the patches health. The complete act is to use the time for fuel that mitochondria oxidize cleanly, circadian amplitude that times biogenesis and redox rhythms, and strength that writes shear and raises apoptosis thresholds in lifelong cells. Sudden monocular vision loss on the combination is an energy emergency, not a curiosity.

Sudden loss of vision in one eye, even if it clears, is an emergency: go to an emergency department right away, because a blocked eye artery is treated like a stroke. In anyone over 50, new headache, jaw pain when chewing, or scalp tenderness with vision loss can mean giant cell arteritis, which needs treatment the same day to protect the other eye. Anyone on semaglutide or a similar drug who has sudden vision loss should also tell the prescribing physician without delay.

Scaling to the Organism

The same architecture operates at larger scale. Coronary occlusion is the cardiac expression of the arterial pathway: plaque rupture or erosion on a background of endothelial NO loss and macrophage mitochondrial distress. Cerebral arterial infarction follows the identical sequence in the carotid or intracranial tree. Peripheral arterial occlusion is the same process in larger conduits that serve skeletal muscle. In each case the final thrombus is the event that brings the patient to attention; the decades-long preparation of the wall is the disease.

Venous thromboembolism follows the low-shear pathway. Prolonged immobility, surgery, or pregnancy supplies stasis. Cancer, inflammation, or hormonal states supply hypercoagulability. The prepared endothelium—already expressing adhesion molecules and tissue factor because of chronic NO loss and mitochondrial impairment—supplies the third element of Virchow’s triad. Obesity and insulin resistance appear in both arterial and venous risk tables because they are systemic expressions of the same cellular energy failure: impaired oxidative phosphorylation, compensatory hyperinsulinemia, hepatic over-secretion of apoB particles, and a redox environment that uncouples eNOS. Ferritin elevation in this setting is often the sentinel reporting that iron is being held because the system perceives ongoing redox threat.

Discordant phenotypes are explained rather than treated as exceptions. Lean individuals with high energy flux, intact glycocalyx, and coupled eNOS can tolerate elevated apoB particle numbers with little plaque because the wall remains competent to handle the particles it encounters. Individuals with mitochondrial inefficiency develop endothelial dysfunction, retention, and inflammation at lower particle numbers. The dashboard (apoB, blood pressure, glucose, ferritin) moves because the engine has already failed. Occlusion, arterial or venous, is the point at which the failed engine can no longer keep the conduit patent under ordinary load.

Therapeutic Implications Inside EnSurf

If both arterial and venous occlusions are downstream of mitochondrial and nitric-oxide failure, prevention and treatment begin with restoration of the flux manager and the engine it serves.

Fuel that mitochondria oxidize cleanly reduces electron leak and the superoxide that uncouples eNOS. Animal proteins and fats, metabolizable carbohydrates in physiologic amounts, and strategic fasting lower the ambient oxidative load. Fasting is not safe for everyone. People taking insulin or other blood-sugar-lowering drugs, people with a primary mitochondrial disease or a heart-rhythm problem, and anyone pregnant should fast only under their physician's care, and fasting should never mean going short on fluids, since dehydration thickens the blood. Circadian alignment—morning light, consistent sleep, dim evenings—supports the daily transcription of eNOS, tetrahydrobiopterin synthesis, and mitochondrial quality control. Strength and conditioning supply the repeated laminar shear that phosphorylates eNOS acutely and writes more of the enzyme over time, while raising tissue mitochondrial volume. Grip strength and functional capacity remain practical surrogates of the whole stack. Where iron handling is shifted toward sequestration, these inputs can reduce the chronic redox and inflammatory signals that drive excessive containment, improving functional iron availability without reflexive supplementation or chelation.

Pharmacologic amplifiers have defined places as bridges, not substitutes. Statins lower apoB and modulate inflammatory cascades; they retain a role in secondary prevention and advanced disease. Antiplatelet agents address the high-shear, platelet-rich phase of arterial thrombosis. Anticoagulation has a place when a physician finds atrial fibrillation or a clinically significant clotting disorder that calls for it; it is not a routine treatment for retinal vein occlusion itself. PDE5 inhibitors amplify residual NO–cGMP signaling and may improve endothelial function in men who already have impairment; they do not restore a pulse that is absent, and they carry a rare reported association with NAION, mainly in eyes with a crowded optic disc. GLP-1 agonists can reduce load and inflammatory drive in selected patients. None of these agents replace the shear, fuel, and circadian conditions that keep eNOS coupled and mitochondria competent.

The ordering remains engine first. When mitochondrial oxidative capacity and laminar shear are restored, endothelial NO bioavailability rises, adhesion and permeability fall, and both the arterial wall and the venous endothelium become more tolerant of ordinary mechanical and rheologic stress. ApoB, blood pressure, glucose, and ferritin often improve as dashboard readings of that restoration. In advanced or genetically driven disease the dashboard may still require direct pharmacologic attention; the hypothesis predicts that such attention will be more effective, and residual risk lower, when the engine is no longer the constraint.

Conclusion

Arterial and venous occlusions are not two diseases that happen to share risk factors. They are two geometric expressions of one metabolic failure: the progressive inability of the vascular wall to maintain coupled nitric oxide and competent mitochondria under the loads of ordinary life. Atherosclerosis is the high-shear scar. Venous thrombosis is the low-shear scar. Ferritin elevation is often the sentinel reporting that iron is being contained because redox and inflammatory threat has been registered. The eye, with its shared sheaths, optical accessibility, and immediate functional readout, is the prototype that makes the sequence visible before it declares itself in the heart, brain, or leg. The optic nerve head is the canary that can declare when dashboard rewrites of load and substrate outrun unrepaired reserve.

The remainder of the EnSurf framework is unchanged. Fuel, circadian coherence, and work that writes shear and mitochondrial volume remain the primary interventions. Amplifiers of cGMP, reducers of apoB, and inhibitors of platelet or coagulation pathways are tools for moments when the pulse is weak or the conduit is already compromised. They are not substitutes for restoring the manager that stands between blood and mitochondrion. When that manager is coupled and the toll-keeper is supplied, high energy flux remains possible without the conduit becoming the disease. When the manager fails, delivery fails, matching fails, and occlusion—arterial or venous—is the catastrophe the organism eventually reports.

This essay synthesizes published mechanisms in nitric oxide biology, vascular physiology, mitochondrial respiration, atherosclerosis, iron handling, and the pharmacology of statins and GLP-1 receptor agonists as of 2026. It is a hypothesis, not medical advice. Individual evaluation by a qualified physician remains essential.

Statins, GLP-1 receptor agonists, antiplatelet agents, anticoagulants, PDE5 inhibitors, and nitrates are prescription medicines used only under a physician’s guidance; nothing on this page is a regimen. PDE5 inhibitors must never be combined with nitrates. Talk with your own physician before changing anything.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice.